Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K7 | O43318 | 3/20 | 0.60 |
| ▸ | IRAK4 | Q9NWZ3 | 3/20 | 0.60 |
| ▸ | NTRK1 | P04629 | 7/20 | 0.54 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.54 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.54 |
| ▸ | CDK2 | P24941 | 2/20 | 0.54 |
| ▸ | CDK9 | P50750 | 2/20 | 0.54 |
| ▸ | EGFR | P00533 | 2/20 | 0.50 |
| ▸ | BTK | Q06187 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | JAK3 | P52333 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | SYK | P43405 | 1/20 | 0.47 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.47 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.47 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17915908 | 0.89 | IRAK4 (0.63) | MAP3K7IRAK4NTRK1CCNT1CCNE1 | |
| SCHEMBL270521 | 0.86 | IRAK4 (0.60) | MAP3K7IRAK4NTRK1CCNT1CCNE1 | |
| SCHEMBL12279582 | 0.85 | IRAK4 (0.58) | MAP3K7IRAK4NTRK1CCNT1CCNE1 | |
| SCHEMBL264247 | 0.83 | MAP3K7 (0.56) | MAP3K7IRAK4NTRK1CCNT1CCNE1 | |
| SCHEMBL301348 | 0.83 | EGFR (0.55) | IRAK4NTRK1CDK2EGFRBTK | |
| SCHEMBL305049 | 0.82 | EGFR (0.54) | EGFRBTKJAK3SYKPTK2 | |
| SCHEMBL10260767 | 0.82 | EGFR (0.52) | EGFRBTKJAK3SYKPTK2 | |
| SCHEMBL10261811 | 0.80 | EGFR (0.52) | EGFRBTKJAK3SYK | |
| SCHEMBL305864 | 0.79 | JAK1 (0.59) | JAK3SYK | |
| SCHEMBL271387 | 0.79 | IRAK4 (0.59) | MAP3K7IRAK4NTRK1CCNT1CCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1951684-B1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | TARGEGEN INC (US) | 2016-07-13 | — | — | EP | disclosed |
| US-8133900-B2 | Use of bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-20110269721-A1 | METHODS OF TREATING THALASSEMIA | TARGEGEN, INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110212077-A1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | TARGEGEN, INC. (US) | 2011-09-01 | — | — | US | disclosed |
| US-7528143-B2 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2009-05-05 | — | — | US | disclosed |
| US-20070259904-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2007-11-08 | — | — | US | disclosed |
| US-20070191405-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191405-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | JAK2, TYK2, JAK3 | MAP3K7 35/4885IRAK4 157/4885NTRK1 725/4885 |
| US-20070259904-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | JAK2, TYK2, JAK3 | MAP3K7 35/4885IRAK4 157/4885NTRK1 725/4885 |
| US-20110212077-A1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | JAK2, TYK2, JAK3 | MAP3K7 35/4885IRAK4 157/4885NTRK1 725/4885 |
| US-20110269721-A1 | METHODS OF TREATING THALASSEMIA | JAK2, STAT5A, STAT5B | MAP3K7 1110/4885IRAK4 368/4885NTRK1 4864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.